Dropouts due to adverse events · adults (aged 18‐85)
Comparison 6: SSRIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 7: TCAs may leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 7: TCAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 1: Alpha‐blockers showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
It is very uncertain whether comparison 2: Antipsychotics changes treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (very low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 2: Antipsychotics showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 3: MAOIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 4: NaSSAs may leads to lower treatment efficacy ‐ Treatment response, as measured by the Global… compared with placebo (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 4: NaSSAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in total mortality compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin may leads to lower non‐fatal cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Major bleedinga · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin leads to higher major bleedinga compared with placebo (high certainty).
1 finding from 1 review
Cardiovascular events · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin may leads to lower all cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Emotionalism (primary outcome) · emotionalism after stroke
It is very uncertain whether pharmaceutical interventions changes emotionalism (primary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Emotionalism: mean scores at end of treatment ‐ Pathological Laughter and Crying Scale · emotionalism after stroke
1 finding from 1 review
Depression: Mean scores at end of treatment · emotionalism after stroke
1 finding from 1 review
Cognitive function · emotionalism after stroke
1 finding from 1 review